CroíValve Appoints Jaime Wheeler as Chief Executive Officer

July 31, 2026—CroíValve announced the appointment of Jaime Wheeler as Chief Executive Officer. Headquartered in Dublin, Ireland, CroíValve is a clinical-stage medical device company developing the investigational Duo transcatheter tricuspid coaptation valve system for the treatment of tricuspid regurgitation (TR).

According to CroíValve, Wheeler has more than 25 years of experience in clinical development and business strategy in cardiology and structural heart technologies. Previously, she served as Senior Vice President of Global Clinical Affairs, Transcatheter Heart Valves at Edwards Lifesciences.

In conjunction with Wheeler’s appointment, the company announced Lucy O’Keeffe will transition into the role of Chief Operating Officer. O’Keeffe is the former CEO and a Board member of CroíValve.

“Jaime brings a proven track record in guiding innovative technologies to market, along with leading high performing teams,” commented Bernard Collins, Chairman of CroíValve, in the company’s press release. “Her leadership will be hugely beneficial in guiding the company through its commercialization journey ahead as we expand our United States base and global activities.”

Collins continued, “I would like thank Lucy, on behalf of the board of directors, for her dedication in leading CroíValve successfully through development and initial clinical validation, demonstrating the value proposition of the Duo system.”

CroíValve noted that it recently announced the expansion of its TANDEM II prospective, multicenter study conducted in the United States and European Union to evaluate the safety and performance of the Duo system in patients with severe or greater symptomatic TR.

In June 2026, the company announced the closing of financing that will be used to fund expanded TANDEM II study.